Fredenburgh J C, Stafford A R, Weitz J I
Hamilton Civic Hospitals Research Centre and Department of Medicine, McMaster University, Hamilton, Ontario L8V 1C3, Canada.
J Biol Chem. 2001 Nov 30;276(48):44828-34. doi: 10.1074/jbc.M108710200. Epub 2001 Oct 2.
Thrombin possesses two positively charged surface domains, termed exosites, that orient substrates and inhibitors for reaction with the enzyme. Because the exosites also allosterically modulate thrombin's activity, we set out to determine whether the structure or function of the exosites changes when thrombin forms complexes with antithrombin, heparin cofactor II, or alpha(1)-antitrypsin (M358R), serpins that utilize both, one, or neither of the exosites, respectively. Using a hirudin-derived peptide to probe the integrity of exosite 1, no binding was detected when thrombin was complexed with heparin cofactor II or alpha(1)-antitrypsin (M358R), and the peptide exhibited a 55-fold lower affinity for the thrombin-antithrombin complex than for thrombin. Bound peptide or HD-1, an exosite 1-binding DNA aptamer, was displaced from thrombin by each of the three serpins. Thrombin binding to fibrin also was abrogated when the enzyme was complexed with serpins. These data reveal that, regardless of the initial mode of interaction, the function of exosite 1 is lost when thrombin is complexed by serpins. In contrast, the integrity of exosite 2 is largely retained when thrombin is complexed by serpins, because interaction with heparin or an exosite 2-directed DNA aptamer was only modestly altered. The disorganization of exosite 1 that occurs when thrombin is complexed by serpins is consistent with results of protease sensitivity studies and crystallographic analysis of a homologous enzyme-serpin complex.
凝血酶具有两个带正电荷的表面结构域,称为外位点,可使底物和抑制剂定向与该酶发生反应。由于外位点也通过变构调节凝血酶的活性,我们着手确定当凝血酶与抗凝血酶、肝素辅因子II或α1抗胰蛋白酶(M358R)形成复合物时,外位点的结构或功能是否会发生变化,这些丝氨酸蛋白酶抑制剂分别利用两个外位点之一或都不利用外位点。使用源自水蛭素的肽来探测外位点1的完整性,当凝血酶与肝素辅因子II或α1抗胰蛋白酶(M358R)形成复合物时,未检测到结合,并且该肽对凝血酶 - 抗凝血酶复合物的亲和力比对凝血酶的亲和力低55倍。结合的肽或HD - 1(一种外位点1结合DNA适体)被三种丝氨酸蛋白酶抑制剂中的每一种从凝血酶上置换下来。当该酶与丝氨酸蛋白酶抑制剂形成复合物时,凝血酶与纤维蛋白的结合也被消除。这些数据表明,无论初始相互作用模式如何,当凝血酶与丝氨酸蛋白酶抑制剂形成复合物时,外位点1的功能都会丧失。相比之下,当凝血酶与丝氨酸蛋白酶抑制剂形成复合物时,外位点2的完整性在很大程度上得以保留,因为与肝素或外位点2定向DNA适体的相互作用仅略有改变。当凝血酶与丝氨酸蛋白酶抑制剂形成复合物时发生的外位点1的紊乱与蛋白酶敏感性研究结果以及同源酶 - 丝氨酸蛋白酶抑制剂复合物的晶体学分析结果一致。